To the best of our knowledge, this real‐world study is the first study to compare the efficacy and safety of three generations of EGFR‐TKI and chemotherapy in NSCLC patients harboring non‐ex 20 ins uncommon EGFR mutations. Here, EGFR is linked to non-small cell lung carcinoma.